Clene Inc (CLNN) Stock Price, Quote & News

Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; comp...

Industry: Packaged Foods

Sector: Consumer Defensive

Phone: 801 676 9695

Website: clene.com

Address:

6550 South Millrock Drive, Suite G50, Salt Lake City, United States

PennyMan2029 Mar. 21 at 10:58 PM

$CLNN I just noticed this now. Not sure if anyone else saw it... I like this person's analysis! To the moon ladies and gentlemen! The wait will be worth it soon. Analyst: Sumant Kulkarni Company: Canaccord Genuity Analysis Date: 3/13/26 Rating: Maintains Strong Buy Price Target: Maintains $48 Current Price 3/13/26 : $5.33 Upside 3/13/26: + 801.41%

1 · Reply

HubAllianceModern Mar. 21 at 6:34 PM

$CLNN biotech, just following along.

0 · Reply

heidibio Mar. 20 at 7:52 PM

$CLNN added 🫣

0 · Reply

Mulhollandr Mar. 20 at 7:27 PM

$CLNN I’ve got nothing constructive. F this. I’m not going anywhere though.

1 · Reply

Bbbb44444 Mar. 20 at 7:24 PM

$CLNN Is WWIII bullish? Fuck Trump and the imbecilic grifters that surround him.

0 · Reply

heidibio Mar. 20 at 7:19 PM

$CLNN positive news is always better to release on a Monday. Bad news better to release on Fridays.

1 · Reply

biotrade123 Mar. 20 at 6:17 PM

$CLNN broke 5.50 support??

2 · Reply

Mulhollandr Mar. 20 at 5:07 PM

$CLNN 5.50 is acting support I suppose. I think we all agree though, end of the day all that matters is the fda minutes and nda submission. Right now we are just gonna get jerked around for a while.

1 · Reply

7m3835d3 Mar. 20 at 1:42 PM

$CLNN oh boy, and down we go..news better comes soon

1 · Reply

Ravery Mar. 20 at 12:48 PM

$CLNN This is a preclinical microcap biotech. 10% moves often have nothing to do with the fundamentals of the company, especially when their is no volume behind it. Our fate is in the hands of the FDA. Most of us believe the clinical package in front of the FDA warrants AA. However, the FDA is the FDA. You have to expect the unexpected especially these days. GL longs. Shareholders and patients are set to benefit if CNM-Au8 is approved. Seems foolish no to, considering the unmet need and safety profile.

1 · Reply

Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights

Feb 24, 2026, 8:00 AM EST - 25 days ago

Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts

Feb 19, 2026, 8:30 AM EST - 4 weeks ago

Clene to Present at the Emerging Growth Conference

Jan 12, 2026, 8:30 AM EST - 2 months ago

Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting

Jan 9, 2026, 8:30 AM EST - 2 months ago

Clene Announces Registered Direct Offering of Over $28 Million

Dec 3, 2025, 8:00 AM EST - 3 months ago

Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

Dec 2, 2025, 5:39 PM EST - 3 months ago

Clene to Provide CNM-Au8® ALS Program Update

Nov 20, 2025, 8:00 AM EST - 4 months ago

Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference

Nov 13, 2025, 8:00 AM EST - 4 months ago

Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights

Oct 15, 2025, 8:30 AM EDT - 5 months ago

Clene to Participate in a Panel Discussion at the Maxim Growth Summit

Sep 25, 2025, 8:00 AM EDT - 6 months ago

Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients

Sep 4, 2025, 8:30 AM EDT - 7 months ago

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease

Sep 2, 2025, 8:00 AM EDT - 7 months ago

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 8:38 AM EDT - 7 months ago

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Aug 5, 2025, 8:30 AM EDT - 8 months ago

Clene to Present at the Canaccord 45th Annual Growth Conference

Jun 30, 2025, 8:00 AM EDT - 9 months ago

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Jun 9, 2025, 9:00 AM EDT - 10 months ago

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

May 7, 2025, 8:00 AM EDT - 11 months ago

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Apr 1, 2025, 8:30 AM EDT - 1 year ago

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Mar 6, 2025, 8:30 AM EST - 1 year ago

Clene to Present at the 37TH Annual Roth Conference

Feb 27, 2025, 9:15 AM EST - 1 year ago

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Feb 25, 2025, 8:00 AM EST - 1 year ago

Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction

Dec 10, 2024, 8:30 AM EST - 1 year ago

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Aug 7, 2024, 8:23 AM EDT - 1 year ago

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Jul 11, 2024, 9:00 AM EDT - 1 year ago

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Clene Announces 1-for-20 Reverse Stock Split

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Jun 21, 2024, 7:09 AM EDT - 1 year ago

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Jun 18, 2024, 7:00 AM EDT - 1 year ago

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

May 28, 2024, 7:30 AM EDT - 1 year ago

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

May 14, 2024, 8:00 AM EDT - 2 years ago

Clene to Present at Upcoming May Conferences

May 8, 2024, 8:00 AM EDT - 2 years ago

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

Apr 16, 2024, 4:01 PM EDT - 2 years ago

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Feb 29, 2024, 8:00 AM EST - 2 years ago

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Dec 21, 2023, 11:25 AM EST - 2 years ago

Clene says FDA finds ALS drug data not enough for accelerated nod

Dec 21, 2023, 7:00 AM EST - 2 years ago

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Dec 21, 2023, 7:00 AM EST - 2 years ago

Clene Provides Update on ALS Clinical Development Meeting With FDA

Dec 14, 2023, 8:36 AM EST - 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Nov 7, 2023, 8:00 AM EST - 2 years ago

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Oct 5, 2023, 10:00 AM EDT - 2 years ago

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Sep 25, 2023, 4:00 PM EDT - 2 years ago

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

PennyMan2029 Mar. 21 at 10:58 PM

1 · Reply

HubAllianceModern Mar. 21 at 6:34 PM

$CLNN biotech, just following along.

0 · Reply

heidibio Mar. 20 at 7:52 PM

$CLNN added 🫣

0 · Reply

Mulhollandr Mar. 20 at 7:27 PM

$CLNN I’ve got nothing constructive. F this. I’m not going anywhere though.

1 · Reply

Bbbb44444 Mar. 20 at 7:24 PM

$CLNN Is WWIII bullish? Fuck Trump and the imbecilic grifters that surround him.

0 · Reply

heidibio Mar. 20 at 7:19 PM

$CLNN positive news is always better to release on a Monday. Bad news better to release on Fridays.

1 · Reply

biotrade123 Mar. 20 at 6:17 PM

$CLNN broke 5.50 support??

2 · Reply

Mulhollandr Mar. 20 at 5:07 PM

$CLNN 5.50 is acting support I suppose. I think we all agree though, end of the day all that matters is the fda minutes and nda submission. Right now we are just gonna get jerked around for a while.

1 · Reply

7m3835d3 Mar. 20 at 1:42 PM

$CLNN oh boy, and down we go..news better comes soon

1 · Reply

Ravery Mar. 20 at 12:48 PM

1 · Reply

idyllic421 Mar. 19 at 9:09 PM

$CLNN dropping on no news?

1 · Reply

neuroinvestor3 Mar. 19 at 8:00 PM

$CLNN Is Chidozie back for more? macro environment sux and i can see why folks feel like they should sell any pre-revenue companies.... also f this "wag the dog" Iran war.

2 · Reply

Mulhollandr Mar. 19 at 7:36 PM

$CLNN two days ago we were hoping to break $6 and hold. We did for a day. But there wasn’t enough meaningful volume. I think we are just looking at a shake out. Support is a hell of a lot higher than it was 2 weeks ago. Type C minutes coming in 6 weeks or less.

1 · Reply

biotrade123 Mar. 19 at 6:42 PM

$CLNN hopefully will hold 6?

1 · Reply

Takeover24 Mar. 19 at 3:28 PM

$CLNN The premarket action this morning

0 · Reply

biotrade123 Mar. 19 at 2:00 PM

$CLNN looks like the market expected a pr at open??

1 · Reply

Mulhollandr Mar. 19 at 1:49 PM

$CLNN algos pinning the price.